Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma

被引:71
作者
Nayak, AS
Banov, C
Corren, J
Feinstein, BK
Floreani, A
Friedman, BF
Goldsobel, A
Gottschlich, GM
Hannaway, PJ
Lampl, KL
Lapidus, RJ
Lawrence, M
Lumry, W
Munk, Z
Pearlman, D
Scardella, AT
Schenkel, EJ
Segal, AT
Segall, N
Silverman, B
Shneyer, L
Nolop, KB
Harrison, JE
机构
[1] Asthma & Allergy Res Associates SC, Normal, IL 61761 USA
[2] Peoria Sch Med, Dept Pediat, Peoria, IL USA
[3] Allergy Ctr Charleston PA, Charleston, SC USA
[4] Asthma Ctr Charleston PA, Charleston, SC USA
[5] Allergy Res Fdn Inc, Los Angeles, CA USA
[6] Virginia Allergy & Pulm Associates PC, Richmond, VA USA
[7] Univ Nebraska, Med Ctr, Omaha, NE USA
[8] Allergy Asthma Bronchitis & Immunol Associates, Fountain Valley, CA USA
[9] Allergy & Asthma Associates, San Jose, CA USA
[10] Allergy & Asthma Affiliates Res Ctr, Cincinnati, OH USA
[11] Allergy Affiliates Inc, Salem, MA USA
[12] Asthma & Allergy Associates, Rockville, MD USA
[13] Rocky Mt Pulm Med Clin Res, Wheat Ridge, CO USA
[14] Clin Res Ctr, Taunton, MA USA
[15] Allergy & Asthma Res Associates, Dallas, TX USA
[16] Breco Res, Houston, TX USA
[17] Rockland Pulm Associates PC, Denver, CO USA
[18] St Peters Med Ctr, Ctr Asthma & Allergy, New Brunswick, NJ USA
[19] Valley Clin Res Ctr, Easton, PA USA
[20] Allergy Associates Res, Dallas, TX USA
[21] Georgia Allergy & Resp Inst, Atlanta, GA USA
[22] Long Isl Coll Hosp, Brooklyn, NY 11201 USA
[23] Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA
关键词
D O I
10.1016/S1081-1206(10)62275-2
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Although inhaled glucocorticoids are recommended for all stages of persistent asthma, compliance with long-term therapy is often poor, leading to significant morbidity and mortality. A simplified, once-daily dosing regimen may foster improved compliance. Objective: To compare the efficacy and safety of once-daily (AM) administration of mometasone furoate dry powder inhaler (MF DPI) 200 mu g and 400 mu g with placebo in patients with asthma previously maintained only on short-acting inhaled beta-adrenergic receptor agonists. Methods: This was a 12-week, double-blind, placebo-controlled, parallel group study. The mean change from baseline to endpoint (last treatment visit) for FEV1 was the primary efficacy variable. Results: At endpoint, both doses of MF DPI were significantly more effective than placebo (P less than or equal to .05) in improving FEV1. Based on morning peak expiratory flow rate, once-daily MF DPI 400 mu g was more effective than placebo (P less than or equal to .001) at endpoint. Both active treatments also demonstrated improvement at endpoint in asthma symptom scores, physician-evaluated response to therapy and use of rescue medication. Although both MF DPI dosages were efficacious, MF DPI 400 mu g provided additional improvement in some measures of pulmonary function (eg, morning PEFR) when these agents were administered once daily in the morning, Both doses of MF DPI were well tolerated and treatment-related adverse events occurred at a similar incidence among the three treatment groups. Conclusions: The results of this study indicate that once-daily (AM) MF DPI provides a convenient and effective treatment option for patients with mild or moderate persistent asthma.
引用
收藏
页码:417 / 424
页数:8
相关论文
共 33 条
[1]   DRUG-THERAPY - INHALED GLUCOCORTICOIDS FOR ASTHMA [J].
BARNES, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (13) :868-875
[2]   Efficacy and safety of inhaled corticosteroids - New developments [J].
Barnes, PJ ;
Pedersen, S ;
Busse, WW .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 157 (03) :S1-S53
[3]   CYTOKINE INHIBITION BY A NOVEL STEROID, MOMETASONE FUROATE [J].
BARTON, BE ;
JAKWAY, JP ;
SMITH, SR ;
SIEGEL, MI .
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 1991, 13 (03) :251-261
[4]   Nonadherence in asthmatic patients: is there a solution to the problem? [J].
Bender, B ;
Milgrom, H ;
Rand, C .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1997, 79 (03) :177-185
[5]   A multicenter, placebo-controlled study of twice daily triamcinolone acetonide (800 μg per day) for the treatment of patients with mild-to-moderate asthma [J].
Bernstein, DI ;
Cohen, R ;
Ginchansky, E ;
Pedinoff, AJ ;
Tinkelman, DG ;
Winder, JA .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 101 (04) :433-438
[6]  
Brannan MD, 1996, J ALLERGY CLIN IMMUN, V97, P62
[7]   Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma [J].
Busse, WW ;
Chervinsky, P ;
Condemi, J ;
Lumry, WR ;
Petty, TL ;
Rennard, S ;
Townley, RG .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 101 (04) :457-463
[8]   Once-daily budesonide in mild asthma [J].
Chisholm, SL ;
Dekker, FW ;
Neven, AK ;
Petri, H .
RESPIRATORY MEDICINE, 1998, 92 (03) :421-425
[9]   MEASURING COMPLIANCE WITH INHALED MEDICATION IN ASTHMA [J].
COUTTS, JAP ;
GIBSON, NA ;
PATON, JY .
ARCHIVES OF DISEASE IN CHILDHOOD, 1992, 67 (03) :332-333
[10]   HOW OFTEN IS MEDICATION TAKEN AS PRESCRIBED - A NOVEL ASSESSMENT TECHNIQUE [J].
CRAMER, JA ;
MATTSON, RH ;
PREVEY, ML ;
SCHEYER, RD ;
OUELLETTE, VL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 261 (22) :3273-3277